Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382061 | 0.88 | TYR (0.64) | TYRTDP1LMNAALDH1A1POLB | |
| SCHEMBL7660861 | 0.87 | TYR (0.49) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL7660854 | 0.87 | TYR (0.49) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL12870299 | 0.86 | TDP1 (0.53) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL10031321 | 0.86 | SLC5A1 (0.63) | TYRSLC5A1SLC5A2TDP1ALDH1A1 | |
| SCHEMBL10031325 | 0.86 | SLC5A1 (0.63) | TYRSLC5A1SLC5A2TDP1ALDH1A1 | |
| SCHEMBL10108864 | 0.84 | ALDH1A1 (0.49) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL15198316 | 0.84 | ALDH1A1 (0.49) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL10119569 | 0.84 | ALDH1A1 (0.49) | TYRSLC5A1SLC5A2TDP1LMNA | |
| SCHEMBL15198140 | 0.84 | ALDH1A1 (0.49) | TYRSLC5A1SLC5A2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053330-A1 | Chemical Process | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053330-A1 | Chemical Process | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053330-A1 | Chemical Process | SLC5A2, SLC5A1, UGGT1 | TYR 409/4885SLC5A1 2/4885SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.